SKYE vs. IXHL, PRQR, CAPR, PRLD, IVA, SCPH, CRVO, EBS, GOSS, and RGLS
Should you be buying Skye Bioscience stock or one of its competitors? The main competitors of Skye Bioscience include Incannex Healthcare (IXHL), ProQR Therapeutics (PRQR), Capricor Therapeutics (CAPR), Prelude Therapeutics (PRLD), Inventiva (IVA), scPharmaceuticals (SCPH), CervoMed (CRVO), Emergent BioSolutions (EBS), Gossamer Bio (GOSS), and Regulus Therapeutics (RGLS). These companies are all part of the "pharmaceutical preparations" industry.
Incannex Healthcare (NASDAQ:IXHL) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment, earnings and community ranking.
0.4% of Incannex Healthcare shares are owned by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are owned by institutional investors. 14.6% of Incannex Healthcare shares are owned by company insiders. Comparatively, 0.7% of Skye Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Skye Bioscience has a consensus target price of $22.50, indicating a potential upside of 85.19%. Given Incannex Healthcare's higher probable upside, analysts clearly believe Skye Bioscience is more favorable than Incannex Healthcare.
Incannex Healthcare has a beta of 8.65, meaning that its stock price is 765% more volatile than the S&P 500. Comparatively, Skye Bioscience has a beta of 1.74, meaning that its stock price is 74% more volatile than the S&P 500.
Skye Bioscience received 1 more outperform votes than Incannex Healthcare when rated by MarketBeat users.
In the previous week, Skye Bioscience had 2 more articles in the media than Incannex Healthcare. MarketBeat recorded 4 mentions for Skye Bioscience and 2 mentions for Incannex Healthcare. Skye Bioscience's average media sentiment score of 0.39 beat Incannex Healthcare's score of 0.00 indicating that Incannex Healthcare is being referred to more favorably in the media.
Incannex Healthcare has higher revenue and earnings than Skye Bioscience.
Summary
Incannex Healthcare beats Skye Bioscience on 6 of the 11 factors compared between the two stocks.
Get Skye Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for SKYE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SKYE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skye Bioscience Competitors List
Related Companies and Tools
